Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Interferon α1b in Stage III/IV Melanoma
NCT07586904Phase 1Recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cadonilimab in melanoma, sponsored by Xijing Hospital. Primary endpoints: Systolic blood pressure up to 3 months, Respiratory rate up to 3 months and 17 more. Started May 2025; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07586904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586904.